Facebook Instagram Pinterest Reddit Tumblr X Youtube
  • Home
  • About
  • News
  • Events
  • Shop
  • Directory
  • Contact Us
Search
Sign in
Welcome! Log into your account
Forgot your password? Get help
Password recovery
Recover your password
A password will be e-mailed to you.
PsyNews.com
  • Home
  • About
  • News
  • Events
  • Shop
  • Directory
  • Contact Us
Home Featured Page 175

Featured

Latest
  • Latest
  • Featured posts
  • Most popular
  • 7 days popular
  • By review score
  • Random

Jackie Tileston: Nondual Mysticism, 5-MeO-DMT, and the Trouble with Psychedelic Art

FDA Approves NRx’s Preservative-Free Generic Ketamine, but Its Bid to Ban Rivals’ Products Remains Pending

Weekly Psychedelic Policy Briefing: Oct. 27, 2026

Pharma Moves In: Investors, Developers and Lilly’s Carole Ho at the Psychedelic Healthcare Forum

Mostly Supportive, Somewhat Divided: Stakeholders Respond to FDA’s Psychedelics Docket

Bright Minds Biosciences Initiates Dosing in Phase I Clinical Trial of...

Mindset Pharma Further Expands its IP Portfolio with Three Additional Non-Tryptamine...

Numinus to Participate in the H.C. Wainwright 24th Annual Global Investment...

Optimi Health Enters Into International Collaborative Research and Supply Agreement With...

Bright Minds Biosciences Announces Closing of $4 Million Unit Offering

Mindset Pharma to Participate in the H.C. Wainwright 24th Annual Global...

Braxia Scientific Reports Q1 2023 Financial Results; Launches KetaMD in U.S....

PT351 – Seth Rosenberg – The Trauma In Being Arrested and...

PsyBio Therapeutics Reports Second Quarter 2022 Financial Results

Wesana Announces Second Quarter 2022 Financial Results

Load more

EDITOR PICKS

Jackie Tileston: Nondual Mysticism, 5-MeO-DMT, and the Trouble with Psychedelic Art

FDA Approves NRx’s Preservative-Free Generic Ketamine, but Its Bid to Ban...

Weekly Psychedelic Policy Briefing: Oct. 27, 2026

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY

    ABOUT US
    PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.
    FOLLOW US
    Facebook Instagram Pinterest Reddit Tumblr X Youtube
    ©